Increased risk of secondary breast cancer associated with radiation therapy for Hodgkin’s disease around time of pregnancy

2002 ◽  
Vol 54 (2) ◽  
pp. 143
Author(s):  
J Chen ◽  
D Gaffney ◽  
L Smith
Keyword(s):  
Breast Cancer ◽  
Radiation Therapy ◽  
Hodgkin's Disease ◽  
Hodgkin’S Disease ◽  
Increased Risk ◽  
Secondary Breast Cancer

scholarly journals Screening for breast cancer in women with previous mantle radiotherapy for Hodgkin's disease

2005 ◽  
Vol 8 (10) ◽  
Author(s):  
G. Ralleigh
Keyword(s):  
Breast Cancer ◽  
Radiation Therapy ◽  
Young Adult ◽  
Hodgkin's Disease ◽  
Hodgkin’S Disease ◽  
Lifetime Risk ◽  
Secondary Malignancy ◽  
Screening Methods ◽  
Increased Risk

There is an established increased risk of secondary malignancy following radiation therapy for cancer in childhood or as a young adult. Breast cancer poses a particular problem as the population risk is significant and screening methods are available raising the question of possible screening interventions for women who are at high lifetime risk.

Increased risk of breast cancer in splenectomized patients undergoing radiation therapy for Hodgkin's disease

1997 ◽  
Vol 37 (2) ◽  
pp. 405-409 ◽  
Author(s):  
Chung T. Chung ◽  
Jeffrey A. Bogart ◽  
James F. Adams ◽  
Robert H. Sagerman ◽  
Patricia J. Numann ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Radiation Therapy ◽  
Hodgkin's Disease ◽  
Hodgkin’S Disease ◽  
Increased Risk

Risk of Second Malignancy After Hodgkin’s Disease in a Collaborative British Cohort: The Relation to Age at Treatment

2000 ◽  
Vol 18 (3) ◽  
pp. 498-498 ◽  
Author(s):  
A.J. Swerdlow ◽  
J.A. Barber ◽  
G. Vaughan Hudson ◽  
D. Cunningham ◽  
R.K. Gupta ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lung Cancer ◽  
Cancer Risk ◽  
Gastrointestinal Cancer ◽  
Hodgkin's Disease ◽  
Hodgkin’S Disease ◽  
Chemotherapeutic Agents ◽  
Second Malignancy ◽  
Increased Risk ◽  
Mixed Modality

PURPOSE: To assess long-term site-specific risks of second malignancy after Hodgkin’s disease in relation to age at treatment and other factors. PATIENTS AND METHODS: A cohort of 5,519 British patients with Hodgkin’s disease treated during 1963 through 1993 was assembled and followed-up for second malignancy and mortality. Follow-up was 97% complete. RESULTS: Three hundred twenty-two second malignancies occurred. Relative risks of gastrointestinal, lung, breast, and bone and soft tissue cancers, and of leukemia, increased significantly with younger age at first treatment. Absolute excess risks and cumulative risks of solid cancers and leukemia, however, were greater at older ages than at younger ages. Gastrointestinal cancer risk was greatest after mixed-modality treatment (relative risk [RR] = 3.3; 95% confidence interval [CI], 2.1 to 4.8); lung cancer risks were significantly increased after chemotherapy (RR = 3.3; 95% CI, 2.4 to 4.7), mixed-modality treatment (RR = 4.3; 95% CI, 2.9 to 6.2), and radiotherapy (RR = 2.9; 95% CI, 1.9 to 4.1); breast cancer risk was increased only after radiotherapy without chemotherapy (RR = 2.5; 95% CI, 1.4 to 4.0); and leukemia risk was significantly increased after chemotherapy (RR = 31.6; 95% CI, 19.7 to 47.6) and mixed-modality treatment (RR = 38.1; 95% CI, 24.6 to 55.9). These risks were generally greater after treatment at younger ages: for patients treated at ages younger than 25 years, there were RRs of 18.7 (95% CI, 5.8 to 43.5) for gastrointestinal cancer after mixed-modality treatment, 14.4 (95% CI, 5.7 to 29.3) for breast cancer after radiotherapy, and 85.2 (95% CI, 45.3 to 145.7) for leukemia after chemotherapy (with or without radiotherapy). CONCLUSION: Age at treatment has a major effect on risk of second malignancy after Hodgkin’s disease. Although absolute excess risks are greater for older patients, RRs of several important malignancies are much greater for patients who are treated when young. The increased risk of gastrointestinal cancers may relate particularly to mixed-modality treatment, and that of lung cancer to chemotherapy as well as radiotherapy; there are also well-known increased risks of breast cancer from radiotherapy and leukemia from chemotherapy. The roles of specific chemotherapeutic agents in the etiology of solid cancers after Hodgkin’s disease require detailed investigation.

Mammographic Screening in Women at Increased Risk of Breast Cancer after Treatment of Hodgkin’s Disease

2008 ◽  
Vol 14 (1) ◽  
pp. 39-48 ◽  
Author(s):  
Ava Kwong ◽  
Steven L. Hancock ◽  
Joan R. Bloom ◽  
Sunita Pal ◽  
Robyn L. Birdwell ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Hodgkin's Disease ◽  
Hodgkin’S Disease ◽  
Mammographic Screening ◽  
Increased Risk

Breast cancer in patients irradiated for Hodgkin's disease: a clinical and pathologic analysis of 45 events in 37 patients.

1992 ◽  
Vol 10 (11) ◽  
pp. 1674-1681 ◽  
Author(s):  
J Yahalom ◽  
J A Petrek ◽  
P W Biddinger ◽  
S Kessler ◽  
D D Dershaw ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Hodgkin's Disease ◽  
Hodgkin’S Disease ◽  
Epidemiologic Studies ◽  
Lymphatic Invasion ◽  
Age At Diagnosis ◽  
Prior History ◽  
Pathologic Features ◽  
Increased Risk

PURPOSE To characterize the clinical and pathologic features of patients who developed breast cancer (BC) after treatment for Hodgkin's disease (HD). Recent epidemiologic studies have shown that women who are cured of HD have an increased risk of developing BC. PATIENTS AND METHODS The clinical data, mammograms, and pathologic specimens of 37 women who developed 45 BCs (eight bilateral events), and had a prior history of treatment for HD were analyzed. RESULTS The median age at diagnosis of HD was 27 years (range, 11 to 60). All patients received radiotherapy (RT) to the upper part of their body, and 10 also had chemotherapy for HD. The median interval from the treatment of HD to the diagnosis of BC was 15 years (range, 8 to 34). The median age at diagnosis of BC was 43 years (range, 27 to 75), 41% of patients were 39 years old or younger. Most mammograms (81%) showed abnormal findings of mass and/or microcalcifications. Of the eight patients (22%) with bilateral tumors, four were synchronous and four were metachronous. Involvement of the medial half of the breast occurred more frequently than in patients with primary BC (39% and 21%, respectively; P < .002). But, the histologic types, grades, presence of lymphocytic reaction, and lymphatic invasion were similar to those observed in 935 primary BC patients who were previously analyzed at our center. The 6-year actuarial relapse-free survival (RFS) for node-negative BC after HD was 85%. Node-positive patients had a significantly lower RFS of 33% (P = .002). CONCLUSIONS In comparison to patients with primary BC, patients who develop BC after HD are more likely to be younger, have bilateral disease, and have their tumors more frequently involve the medial half of the breast. Pathologic characteristics, nodal involvement, and prognosis are similar to those of primary BC. BC in women who were treated for HD is becoming an increasing problem, as more patients cured of HD reach a follow-up time of 10 to 15 years. Breast examination and mammography at an early age should be part of the follow-up program for women who are cured of HD.

Sign in / Sign up

Export Citation Format

Share Document